CoChat
Sign Up
Cited by 214Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Amyloid-β, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease: A Multicenter, Prospective Cohort Study

Open access
Pietrzak, Robert H., Lim, Yen Ying, Neumeister, Alexander, Ames, David, Ellis, Kathryn A., Harrington, Karra, Lautenschlager, Nicola T., Restrepo, Carolina, Martins, Ralph N., Masters, Colin L., Villemagne, Victor L., Rowe, Christopher C., Maruff, Paul·2015·JAMA Psychiatry
DOI 10.1001/jamapsychiatry.2014.2476
Open this paper in CoChat — free account

Abstract

IMPORTANCE: Alzheimer disease (AD) is now known to have a long preclinical phase in which pathophysiologic processes develop many years, even decades, before the onset of clinical symptoms. Although the presence of abnormal levels of amyloid-β (Aβ) is associated with higher rates of progression to clinically classified mild cognitive impairment or dementia, little research has evaluated potentially modifiable moderators of Aβ-related cognitive decline, such as anxiety and depressive symptoms. OBJECTIVE: To evaluate the association between Aβ status and cognitive changes, and the role of anxiety and depressive symptoms in moderating Aβ-related cognitive changes in the preclinical phase of AD. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, prospective cohort study with baseline and 18-, 36-, and 54-month follow-up assessments, we studied 333 healthy, older adults at hospital-based research clinics. MAIN OUTCOMES AND MEASURES: Carbon 11-labeled Pittsburgh Compound B (PiB)-, florbetapir F 18-, or flutemetamol F 18-derived measures of Aβ, Hospital Anxiety and Depression Scale scores, and comprehensive neuropsychological evaluation that yielded measures of global cognition, verbal memory, visual memory, attention, language, executive function, and visuospatial ability. RESULTS: A positive Aβ (Aβ+) status at baseline was associated with a significant decline in global cognition, verbal memory, language, and executive function, and elevated anxiety symptoms moderated these associations. Compared with the Aβ+, low-anxiety group, slopes of cognitive decline were significantly more pronounced in the Aβ+, high-anxiety group, with Cohen d values of 0.78 (95% CI, 0.33-1.23) for global cognition, 0.54 (95% CI, 0.10-0.98) for verbal memory, 0.51 (95% CI, 0.07-0.96) for language, and 0.39 (95% CI, 0.05-0.83) for executive function. These effects were independent of age, educational level, IQ, APOE genotype, subjective memory complaints, vascular risk factors, and depressive symptoms; furthermore, depressive symptoms and subjective memory complaints did not moderate the association between Aβ and cognitive decline. CONCLUSIONS AND RELEVANCE: These results provide additional support for the deleterious effect of elevated Aβ levels on cognitive function in preclinical AD. They further suggest that elevated anxiety symptoms moderate the effect of Aβ on cognitive decline in preclinical AD, resulting in more rapid decline in several cognitive domains. Given that there is currently no standard antiamyloid therapy and that anxiety symptoms are amenable to treatment, these findings may help inform risk stratification and management of the preclinical phase of AD.

Overview

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2014.2476

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Flagged first, then by citations

Show all 51 references

Cited by

Sorted by citations

Items 201–214 of 214

Related

See all

Metadata

Authors
Pietrzak, R. H., Lim, Y. Y., Neumeister, A., Ames, D., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Restrepo, C., Martins, R. N., Masters, C. L., Villemagne, V. L., Rowe, C. C., & Maruff, P.
Affiliations
  • United States Department of Veterans Affairs (US)
  • The University of Melbourne (AU)
  • New York University (US)
  • Edith Cowan University (AU)
Corresponding author
Pietrzak, Robert H.
ORCID
Venue
JAMA Psychiatry
Publisher
American Medical Association (AMA)
Published
2015-03-01
Volume
72
Issue
3
Pages
284
ISSN
2168-622X (ISSN-L)
DOI
10.1001/jamapsychiatry.2014.2476
OpenAlex
W2049932209
Cited by
214
References
51
Citations by year
2026: 13 · 2025: 16 · 2024: 24 · 2023: 17 · 2022: 22 · 2021: 27 · 2020: 19 · 2019: 15 · 2018: 15 · 2017: 20 · 2016: 15 · 2015: 10
FWCI
16.22
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • JAMA Psychiatry (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • Australasian Journal of Paramedicine (submittedVersion)
  • Swinburne figshare (Swinburne University of Technology) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
amyloid-beta, preclinical Alzheimer's disease, anxiety, cognitive decline, depressive symptoms, moderating effect, amyloid PET, Pittsburgh compound B, florbetapir, verbal memory, executive function, language, global cognition, older adults, subjective memory complaints, APOE genotype, mild cognitive impairment, dementia risk
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Anxiety, Depression, Female, Genotype, Humans, Male, Middle Aged, Neuropsychological Tests, Prospective Studies, Amyloid beta-Peptides, Disease Progression, Positron-Emission Tomography, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review